135 related articles for article (PubMed ID: 32796361)
1. Serial measurements of faecal calprotectin may discriminate intestinal tuberculosis and Crohn's disease in patients started on antitubercular therapy.
Sharma V; Verma S; Kumar-M P; Mandavdhare HS; Singh H; Shah J; Kalsi D; Dutta A; Mishra S; Prasad KK; Sharma AK; Dutta U
Eur J Gastroenterol Hepatol; 2021 Mar; 33(3):334-338. PubMed ID: 32796361
[TBL] [Abstract][Full Text] [Related]
2. Association of Faecal Calprotectin Level and Combined Endoscopic and Radiological Healing in Patients With Crohn's Disease Receiving Anti-tumour Necrosis Factor Therapy.
Noh SM; Oh EH; Park SH; Lee JB; Kim JY; Park JC; Kim J; Ham NS; Hwang SW; Park SH; Yang DH; Byeon JS; Myung SJ; Yang SK; Ye BD
J Crohns Colitis; 2020 Sep; 14(9):1231-1240. PubMed ID: 32157278
[TBL] [Abstract][Full Text] [Related]
3. High faecal calprotectin levels in intestinal tuberculosis are associated with granulomas in intestinal biopsies.
Larsson G; Shenoy KT; Ramasubramanian R; Thayumanavan L; Balakumaran LK; Bjune GA; Moum BA
Infect Dis (Lond); 2015 Mar; 47(3):137-43. PubMed ID: 25522183
[TBL] [Abstract][Full Text] [Related]
4. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study.
Laharie D; Mesli S; El Hajbi F; Chabrun E; Chanteloup E; Capdepont M; Razaire S; de Lédinghen V; Zerbib F
Aliment Pharmacol Ther; 2011 Aug; 34(4):462-9. PubMed ID: 21671970
[TBL] [Abstract][Full Text] [Related]
5. A simple method for assessing intestinal inflammation in Crohn's disease.
Tibble J; Teahon K; Thjodleifsson B; Roseth A; Sigthorsson G; Bridger S; Foster R; Sherwood R; Fagerhol M; Bjarnason I
Gut; 2000 Oct; 47(4):506-13. PubMed ID: 10986210
[TBL] [Abstract][Full Text] [Related]
6. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.
Guidi L; Marzo M; Andrisani G; Felice C; Pugliese D; Mocci G; Nardone O; De Vitis I; Papa A; Rapaccini G; Forni F; Armuzzi A
Dig Liver Dis; 2014 Nov; 46(11):974-9. PubMed ID: 25096964
[TBL] [Abstract][Full Text] [Related]
7. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment.
Sipponen T; Björkesten CG; Färkkilä M; Nuutinen H; Savilahti E; Kolho KL
Scand J Gastroenterol; 2010 Mar; 45(3):325-31. PubMed ID: 20034360
[TBL] [Abstract][Full Text] [Related]
8. Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab.
Bertani L; Fornai M; Fornili M; Antonioli L; Benvenuti L; Tapete G; Baiano Svizzero G; Ceccarelli L; Mumolo MG; Baglietto L; de Bortoli N; Bellini M; Marchi S; Costa F; Blandizzi C
Aliment Pharmacol Ther; 2020 Jul; 52(2):284-291. PubMed ID: 32506635
[TBL] [Abstract][Full Text] [Related]
9. Elevated Faecal Calprotectin Levels are a Reliable Non-Invasive Screening Tool for Small Bowel Crohn's Disease in Patients Undergoing Capsule Endoscopy.
Yousuf H; Aleem U; Egan R; Maheshwari P; Mohamad J; McNamara D
Dig Dis; 2018; 36(3):202-208. PubMed ID: 29466790
[TBL] [Abstract][Full Text] [Related]
10. Accurate cut-offs for predicting endoscopic activity and mucosal healing in Crohn's disease with fecal calprotectin.
Vázquez Morón JM; Pallarés Manrique H; Machancoses FH; Ramos Lora M; Ruiz Frutos C
Rev Esp Enferm Dig; 2017 Feb; 109(2):130-136. PubMed ID: 28071062
[TBL] [Abstract][Full Text] [Related]
11. Correlation between faecal calprotectin and magnetic resonance imaging (MRI) in the evaluation of inflammatory pattern in Crohn's disease.
Zippi M; Al Ansari N; Siliquini F; Severi C; Kagarmanova A; Maffia C; Parlanti S; Garbarino V; Maccioni F
Clin Ter; 2010; 161(2):e53-6. PubMed ID: 20499020
[TBL] [Abstract][Full Text] [Related]
12. Endoscopic and clinical responses to anti-tubercular therapy can differentiate intestinal tuberculosis from Crohn's disease.
Pratap Mouli V; Munot K; Ananthakrishnan A; Kedia S; Addagalla S; Garg SK; Benjamin J; Singla V; Dhingra R; Tiwari V; Bopanna S; Hutfless S; Makharia G; Ahuja V
Aliment Pharmacol Ther; 2017 Jan; 45(1):27-36. PubMed ID: 27813111
[TBL] [Abstract][Full Text] [Related]
13. Routine diagnosis of intestinal tuberculosis and Crohn's disease in Southern India.
Larsson G; Shenoy T; Ramasubramanian R; Balakumaran LK; Småstuen MC; Bjune GA; Moum BA
World J Gastroenterol; 2014 May; 20(17):5017-24. PubMed ID: 24803814
[TBL] [Abstract][Full Text] [Related]
14. Associations Among Mucosal and Transmural Healing and Fecal Level of Calprotectin in Children With Crohn's Disease.
Weinstein-Nakar I; Focht G; Church P; Walters TD; Abitbol G; Anupindi S; Berteloot L; Hulst JM; Ruemmele F; Lemberg DA; Leach ST; Cytter R; Greer ML; Griffiths AM; Turner D;
Clin Gastroenterol Hepatol; 2018 Jul; 16(7):1089-1097.e4. PubMed ID: 29501599
[TBL] [Abstract][Full Text] [Related]
15. The combination of fecal calprotectin with ESR, CRP and albumin discriminates more accurately children with Crohn's disease.
Daniluk U; Daniluk J; Krasnodebska M; Lotowska JM; Sobaniec-Lotowska ME; Lebensztejn DM
Adv Med Sci; 2019 Mar; 64(1):9-14. PubMed ID: 30237086
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Crohn's disease activity: initial validation of a magnetic resonance enterography global score (MEGS) against faecal calprotectin.
Makanyanga JC; Pendsé D; Dikaios N; Bloom S; McCartney S; Helbren E; Atkins E; Cuthbertson T; Punwani S; Forbes A; Halligan S; Taylor SA
Eur Radiol; 2014 Feb; 24(2):277-87. PubMed ID: 24026620
[TBL] [Abstract][Full Text] [Related]
17. Faecal calprotectin is the biomarker that best distinguishes remission from different degrees of endoscopic activity in Crohn's disease.
E Penna FGC; Rosa RM; da Cunha PFS; de Souza SCS; de Abreu Ferrari ML
BMC Gastroenterol; 2020 Feb; 20(1):35. PubMed ID: 32054445
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of a rapid faecal calprotectin test to predict relapse in Crohn's disease patients on maintenance treatment with adalimumab.
Ferreiro-Iglesias R; Barreiro-de Acosta M; Lorenzo-Gonzalez A; Dominguez-Muñoz JE
Scand J Gastroenterol; 2016; 51(4):442-7. PubMed ID: 26595391
[TBL] [Abstract][Full Text] [Related]
19. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease.
Sipponen T; Savilahti E; Kärkkäinen P; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
Inflamm Bowel Dis; 2008 Oct; 14(10):1392-8. PubMed ID: 18484671
[TBL] [Abstract][Full Text] [Related]
20. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.
Schoepfer AM; Beglinger C; Straumann A; Trummler M; Vavricka SR; Bruegger LE; Seibold F
Am J Gastroenterol; 2010 Jan; 105(1):162-9. PubMed ID: 19755969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
